BofA lowered the firm’s price target on Pfizer (PFE) to $26 from $29 and keeps a Neutral rating on the shares. For Q1, the firm’s total revenue estimates decline by 2% due to Part D assumptions as well as adjustments to Paxlovid seasonality, while for 2025 it made no major changes, but notes that revenue estimates increase less than1%, partly due to foreign exchange assumptions, the analyst tells investors in a preview.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer’s Uncertain Growth Prospects and Industry Challenges Justify Hold Rating
- Eli Lilly Stock (LLY) Goes Supersized after New Oral Weight Loss Drug Impresses in Trials
- ACIP votes to expand recommendation for Pfizer’s RSV vaccine
- Trump’s Executive Order on Healthcare Aims to Lower Drug Costs for Americans
- Pfizer’s Undervalued Potential: Strong Buy Rating Amid Strategic Growth and Resilience